东诚药业：上半年营收下滑2.6%至13.84亿元，硫酸软骨素产品收入上升4.26%

Core Insights - Dongcheng Pharmaceutical reported a 2.6% decline in revenue for the first half of 2025, totaling 1.384 billion yuan, with net profit attributable to shareholders decreasing by 20.70% to 88.6525 million yuan [1] Revenue Breakdown - The nuclear medicine segment generated sales of 503 million yuan, a year-on-year increase of 0.78%, with the key product F-FDG achieving revenue of 212 million yuan, up 8.72% due to increased sales volume [1] - The sales of Yunk injection solution reached 116 million yuan, down 5.69% year-on-year, while iodine-sealed seeds generated revenue of 70.8919 million yuan, a decrease of 8.34% [1] - The raw material drug segment reported sales of 611 million yuan, a decline of 7.02%, with heparin raw material products generating 440 million yuan, down 8.90% primarily due to falling sales prices of heparin sodium [1] - Chondroitin sulfate products achieved sales of 165 million yuan, an increase of 4.26% [1] - The formulation segment recorded sales of 182 million yuan, a year-on-year increase of 1.76%, with the key product nadroparin calcium injection generating revenue of 77.2931 million yuan, up 6.30% [1]